Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

BMS-303141

Catalog No: tcsc2039

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Specifications

CAS No:
943962-47-8

Formula:
$C_{19}H_{15}Cl_2NO_4S$

Pathway:
Metabolic Enzyme/Protease

Target:
ATP Citrate Lyase

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 47 mg/mL (110.77 mM)

Observed Molecular Weight:
424.3

Product Description

BMS-303141 is a potent, cell-permeable ATP-citrate lyase (**ACL**) inhibitor with an **IC_{50}** value of 0.13 μM.

IC50 & Target: IC50: 0.13 uM (ACL)[1]

In Vitro:

Copyright 2021 Taiclone Biotech Corp.

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

In HepG2 cells, BMS-303141 shows inhibition of total lipid syntheses with an IC_{50} of 8 μM. BMS-303141 shows no cytotoxicity up to 50 lM under a cell based Alamar Blue cytotoxicity assay, indicating the observed inhibition of lipid synthesis is not a result of compound-induced cytotoxicity[1].

In Vivo: Chronic oral dosing of BMS-303141 in high-fat fed mice lowers approximate 20-30% plasma cholesterol and triglycerides, as well as 30-50% fasting plasma glucose. Chronic treatment with BMS-303141 shows a gradual inhibition of weight gain along with a reduction in adiposity without apparent changes in food intake. BMS-303141 shows an oral bioavailability of 55% but a relatively short half-life of 2.1 h[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.